Eculizumab, a monoclonal antibody, is indicated for the treatment of two rare and life-threatening conditions: Paroxysmal Nocturnal Hemoglobinuria (PNH), a blood disorder that destroys red blood cells and causes blood clots and organ damage, and Atypical Hemolytic Uremic Syndrome (aHUS), which leads to abnormal blood clotting, often resulting in kidney failure and other complications. The drug works by inhibiting complement-mediated thrombotic microangiopathy, a condition that underlies both PNH and aHUS.
Asmita Pant is a journalist for CNBC-TV18, focusing on national news in India. With a keen interest in business and entertainment, Asmita covers a wide range of topics including stock market updates, corporate news, and cultural events. Her articles provide insights into the Indian economy, business trends, and the entertainment industry.